As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck. Following on from advice received from the company, the timelines for this appraisal are currently to be confirmed and therefore the appraisal is suspended. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties as and when the situation changes
 
Status Suspended
Process STA pre-2018
ID number 1140

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
03 September 2018 Suspended, As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck. Following on from advice received from the company, the timelines for this appraisal are currently to be confirmed and therefore the appraisal is suspended. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties as and when the situation changes
09 February 2018 As you will be aware, the Department of Health has asked NICE to conduct an appraisal of pembrolizumab for untreated, recurrent or metastatic squamous cell carcinoma of the head and neck. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early October 2018 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early December 2018
14 September 2017 As you will be aware, the Department of Health has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck. Following on from advice received from the company, the timelines for this appraisal are currently to be confirmed. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties when the situation changes.
28 June 2017 - 26 July 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
01 March 2017 Referral
01 March 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance